Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) expects a significant increase in net profit attributable to shareholders for 2025, projecting between 113 million to 137 million yuan, representing a growth of 119.57% to 166.20% year-on-year [1] Financial Performance - The net profit after deducting non-recurring gains and losses is anticipated to be between 82 million to 106 million yuan, indicating a substantial increase of 782.01% to 1,040.17% compared to the previous year [1] - The expected impact of non-recurring gains and losses on the net profit attributable to shareholders is approximately 31 million yuan [1] Business Drivers - The significant growth in operating performance for 2025 is primarily driven by the lithium hexafluorophosphate business [1] - The demand in the new energy vehicle market and the rapid growth in the energy storage market have notably improved the profitability of the company's lithium hexafluorophosphate business [1]
宏源药业(301246.SZ)：预计2025年净利润同比增长119.57%～166.2%